

ASX Release

**Oventus enters into initial agreements with Canadian sleep medicine groups who will deliver the O<sub>2</sub>Vent® Sleep Treatment Platform to patients under the 'lab in lab' model**

**Key points:**

- **Oventus signs first material agreements with sleep medicine groups in Canada for its O<sub>2</sub>Vent® Sleep Treatment Platform which treats obstructive sleep apnoea (OSA)**
- **The exclusive supply agreements are with two sleep groups in Canada which represent 7 clinical delivery sites**
- **Oventus expects to secure further agreements across North America over the next 12-24 months**
- **Negotiations ongoing with multiple groups across Canada, the US and Australia with a view to significant scaling through the end of calendar 2019 and 2020**

Brisbane, Australia 24 June 2019: Oventus Medical Ltd or the Company (ASX: OVN) is pleased to announce it has signed its first material contracts with Canadian sleep medicine groups who will adopt the Company's O<sub>2</sub>Vent® Sleep Treatment Platform. The launch with the two groups, which represent 7 clinical delivery sites, is scheduled for July 2019.

The exclusive supply agreements require that each of the 7 sites must deliver minimum monthly quotas of 20 devices from the O<sub>2</sub>Vent® Sleep Treatment Platform, which will be delivered to patients using the 'lab in lab' model. The Oventus Sleep Treatment Platform encompasses the O<sub>2</sub>Vent® oral therapeutic device, and the unique valve accessories, ExVent™ and O<sub>2</sub>Vent® OnePAP™\*.

CEO of Oventus, Dr Chris Hart commented, "We have been working hard over the past 18 months to educate sleep clinicians and dentists on the benefits of our Sleep Treatment Platform, which is delivering therapeutic outcomes similar to CPAP for the majority of OSA patients. These first contracts are representative of a significant pipeline of interest in our technology and strong validation that our 'lab in lab' model can make commercial sense."

Oventus is in ongoing negotiations with multiple groups across Canada, the US and Australia for the adoption of its technology and the 'lab in lab' model with a view to significant scaling through the end of calendar 2019 and 2020. Further agreements of this kind are expected to be secured and announced across these key markets over the next 12-24 months.

\*The O<sub>2</sub>Vent® OnePAP™ product is not yet in-market.



# BETTER SLEEP, BETTER HEALTH and a BETTER LIFE

For further information, please visit our website at [www.o2vent.com](http://www.o2vent.com) or contact the individuals outlined below.

Dr Chris Hart, Managing Director and CEO: M: +61 409 647 496

Jane Lowe, IR Department: M: +61 411 117 774 or [jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)

## About Oventus

Oventus is a Brisbane based medical device company that is commercialising a unique treatment platform for the treatment of sleep apnoea and snoring. Unlike other oral appliances or CPAP interfaces, the Oventus devices have a unique and patented airway within the treatment platform that allows air to flow to the back of the mouth unobstructed while maintaining an oral seal and stable jaw position, bypassing multiple obstructions from the nose, soft palate and tongue. The devices reduce airway collapsibility and manage mouth breathing while maintaining a stable airway with or without nasal CPAP. They are particularly designed for the many people that have nasal obstructions and consequently tend to mainly breathe through their mouth. While it may seem counterintuitive, this technology actually manages mouth breathing by converting it to device breathing and normalising ventilation. The O<sub>2</sub>Vent<sup>®</sup> is designed to allow nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airways in the appliance.

According to a report published by the Sleep Health Foundation Australia, an estimated 1.5 million Australians suffer with sleep disorders and more than half of these suffer with obstructive sleep apnoea.<sup>1</sup>

Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnoea, however many patients have difficulty tolerating CPAP<sup>2</sup>. Oral appliances have emerged as an alternative to CPAP for obstructive sleep apnoea treatment.<sup>3</sup>

<sup>1</sup> Deloitte Access Economics. *Reawakening Australia: the economic cost of sleep disorders in Australia, 2010*. Canberra, Australia.

<sup>2</sup> Beecroft, et al. *Oral continuous positive airway pressure for sleep apnea; effectiveness, patient preference, and adherence*. *Chest* 124:2200–2208, 2003

<sup>3</sup> Sutherland et al. *Oral appliance treatment for obstructive sleep apnea: An updated Journal of Clinical Sleep Medicine*. February 2014.